- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - - Further strengthens balance sheet with pro forma cash position >$2.1 billion - ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transfo ...

 —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $70.01, marking a +1.71% move from the previous day. This change outpaced the S&P 500's 0.57% gain on the day. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, added 1.25%.Prior to today's trading, shares of the company had gained 6.15% over the past month. This has outpaced the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time.Analysts and investors alike will be keeping a close eye on the per ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $64.75, moving +0.12% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.07%. Elsewhere, the Dow saw an upswing of 0.35%, while the tech-heavy Nasdaq appreciated by 1.74%.The company's shares have seen an increase of 4.41% over the last month, surpassing the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93%.The investment community will be paying close attention to the earnings p ...

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world. This gives buyers a number of choices for adding investments that will make them money to their accounts.With only a few weeks left in the year, it’s clear that healthcare stocks are more than just a trend. Because they are strong and last a long time, they are a good purchase. In 2024, healthcare stocks will ...

CRISPR Therapeutics (CRSP 7.82%) soared 54% last year as growth stocks rallied and the company itself moved toward an important milestone: the approval of its very first product. The gene editing specialist won the world's first nod for a CRISPR-based gene editing therapy back in November when the U.K. authorized Casgevy for sickle cell disease and beta thalassemia. Then the U.S. went on to approve the product for both blood disorders too.What this means is CRISPR Therapeutics this year should start reporti ...

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (CRSP 1.46%) earned approval for its first therapy late last year. The treatment in question is called Casgevy and targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), two blood-related diseases. This regulatory development was a significant milestone for CRISPR, but the biotech will need more clinical and regulatory success in the years ahead to keep investors happy.Can CRISPR ...

With CRISPR Therapeutics (CRSP 5.28%) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process and a quickly expanding development pipeline, it's certainly true that it has more than one opportunity at impressing the market and enriching its shareholders.Still, even the most successful companies experience setbacks from time to time, and this biotec ...

Editas Medicine (EDIT -0.98%) and CRISPR Therapeutics (CRSP 1.66%) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets.But as you may have heard, with the recent launch of its first gene therapy, called Casgevy, CRISPR Therapeutics is now a revenue-stage biote ...

Many stocks that have delivered big gains eventually succumb to the investing equivalent of gravity. However, not all of them do. Some keep the momentum going and going.Three Motley Fool contributors think that they've found high-flying stocks that can go much higher in 2024. Here's why they picked CRISPR Therapeutics (CRSP 1.66%), Eli Lilly (LLY 0.84%), and Novo Nordisk (NVO -0.55%).This biotech still has room to run higherDavid Jagielski (CRISPR Therapeutics): One stock that I don't expect to slow down th ...